Risedronate for the prevention and treatment of corticosteroid-induced osteoporosis.
OBJECTIVE
To evaluate the role of risedronate in corticosteroid-induced osteoporosis.


METHODS
Clinical literature was accessed through MEDLINE (1966-February 2001). Key search terms included risedronate, corticosteroid, osteoporosis, and bisphosphonate.


RESULTS
Corticosteroid-induced osteoporosis (CIO) is clinically challenging and can lead to fractures. Risedronate, an oral bisphosphonate, has been studied for use in CIO. Trials focusing on the use of risedronate in these patients were reviewed.


CONCLUSIONS
Risedronate 5 mg/d increased bone mineral density at lumbar, femoral neck, and trochanter skeletal sites in patients recently initiated on or receiving long-term corticosteroid therapy. Further investigation is needed to determine risedronate's effects on fracture prevention. The drug was well tolerated.
Dougherty
John A
JA
College of Pharmacy & Allied Health Professions, Wayne State University, Detroit, MI, USA. jdougher@dmc.org
D000305:Adrenal Cortex Hormones / Q000009:adverse effects*; D015519:Bone Density / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D012968:Etidronic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control; D016032:Randomized Controlled Trials as Topic; D000068296:Risedronic Acid
D000305:Adrenal Cortex Hormones; D002121:Calcium Channel Blockers; D000068296:Risedronic Acid; D012968:Etidronic Acid